Product Description
Mechanisms of Action: TXA2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Institut de Recherches Internationales Servier
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
PERFORM | P3 |
Completed |
Stroke |
2010-01-27 |
|
2007-000176-17 | P2 |
Completed |
Stroke |
2009-04-20 |